Efficacy of n-3 polyunsaturated fatty acids in hemodialysis patients with dyslipidemia

Efficacy of n-3 polyunsaturated fatty acids in hemodialysis patients with dyslipidemia - Efficacy of n-3 polyunsaturated fatty acids in hemodialysis patients with dyslipidemia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017853

Enrollment

Registered

2015-06-10

Start date

2015-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease, dyslipidemia

Interventions

4g of omega-3 fatty acid ethyl granular capsule for 3 months no administration of omega-3 fatty acid ethyl granular capsule for 3 months, then 2g administration of omega-3 fatty acid ethyl granular ca

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age of 20 years old or older 2. Patients without administration of n-3 polyunsaturated fatty acids (including supplements) at least for 6 months 3. Patients who have voluntarily provided written informed consent after fully understanding the information given about participation in the study.

Exclusion criteria

Exclusion criteria: 1. History of allergy to n-3 polyunsaturated fatty acids 2. Pregnant women or women suspected of being pregnant 3. Patients who have active bleeding 4. Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
evaluation of changes in atherosclerosis indexes, blood pressure variability	—

Secondary

Measure	Time frame
changes in coagulation, inflammation-related index and dialysis-related index	—

Countries

Japan

Contacts

Public ContactYusuke Kobayashi

Yokosuka city hospital Division of nephrology

yusuke.kob@live.jp046-856-3136

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026